Advertisement

Advertisement

2018 ASH Annual Meeting

Advertisement

Advertisement

Apr

21

Today In Oncology

FDA Pipeline: Designations for Myelodysplastic Syndromes, Triple-Negative Breast Cancer, AML, and EBV-Associated Cancers

NRG1 Gene Fusions Detected at Low Incidence Across Multiple Tumor Types

Primary Surgery Outcomes in MRI-Based ‘Good-Prognosis’ Rectal Cancer

Patient-Reported Outcomes With Salvage Autologous Stem Cell Transplantation vs Nontransplantation in Relapsed Multiple Myeloma

Study Finds Medicaid Reimbursement for Radiation Therapy Varies Widely State-to-State

;

Advertisement

Most Read Stories

FDA Grants Accelerated Approval to Erdafitinib for Metastatic Urothelial Carcinoma

ASCO and ASH Release Update to Clinical Practice Guidelines for Use of Erythropoiesis-Stimulating Agents

Follow-up of Adjuvant Paclitaxel and Trastuzumab in Small HER2-Positive Breast Tumors

When Can Patients With Gleason 6 Prostate Cancer Safely Undergo Active Surveillance?

Complementary and Alternative Medicine Use in Patients With Cancer

Most Viewed Videos

William J. Gradishar, MD, on HR-Positive, HER2-Negative Advanced Breast Cancer: NCCN Guidelines Updates

Sagar Lonial, MD, on Multiple Myeloma: Sequencing Therapies

Wells A. Messersmith, MD, on Managing Metastatic Colorectal Cancer: NCCN Guidelines Update

Julie M. Vose, MD, MBA, on Lymphoma: Novel Pathways for Targeted Agents

Nicholas Vogelzang, MD, on Urothelial Cancer: Results From a Trial on Lenvatinib Plus Pembrolizumab

© 2019 HSP News Service, L.L.C.